Please assess the completion status of the following clinical trial:

Trial Title: AIDS Vaccine Study Comparing Immunogenicity and Safety of 3 Doses of Lipopeptides Versus Placebo in Non Infected HIV Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteers selected by ANRS (French National Agency for Research on AIDS and Viral Hepatitis)~* For woman of child-bearing age: use of effective contraception~* Ability to sign informed consent~* Beneficiary subjects of social security regimen-- Hepatitis B, hepatitis C, HIV, HTLV1 infection and syphilis negative~* Hemoglobin over 12.5 g/dl for women and over 13.5 g/dl for men~Exclusion Criteria:~* Previous participation in an HIV clinical trial~* Volunteers with risk to contract HIV infection during the trial~* Previous vaccination in the last month, and volunteers requiring vaccination during the trial~* Gift of blood in the last 2 months~* Eczema, urticaria~* Medical history of food allergy, Lyell or Stevens Johnson syndrome and aggravated asthma~* Previous (last 6 months) or ongoing administration of immunological treatment, chemotherapy, radiotherapy or corticosteroid~* Medical history of autoimmune disease~* Clinical or biological aftermath of previous disease~* Medical history of uveitis~* Transfusion in the last 6 months

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).